Tibet Aim Pharm Inc

Tibet Aim Pharm Inc has a liquidity position that is relatively strong, with a current ratio of 2.7, indicating that the company has 2.7 times more current assets than current liabilities. However, the company's net cash position is negative after subtracting total debt, which raises some liquidity concerns. The company's long-term debt is relatively low at 11 million CNY, and its total liabilities are 192.89 million CNY, compared to total equity of 730.86 million CNY, resulting in a debt-to-equity ratio of 0.02.

In terms of profitability, Tibet Aim Pharm Inc has a return on equity (ROE) of 1.61% and a return on assets (ROA) of 1.27%, which are both below the typical thresholds for strong performance in the pharmaceutical industry. The company's net income is 11.75 million CNY, and its operating income is 14.01 million CNY, suggesting that the company is generating modest profits relative to its revenue of 191.56 million CNY.

The company's revenue is concentrated in a single geographic market, primarily China, and there is no indication of significant diversification across product segments or geographic regions. This concentration could expose the company to regional economic or regulatory risks, which may affect its long-term stability and growth potential.

Tibet Aim Pharm Inc's growth trajectory appears to be modest, with no specific numeric deltas provided for the current or next fiscal year. The company's capital expenditures are negative at -8.14 million CNY, indicating that it is not investing heavily in new assets or expansion. This could suggest a conservative approach to growth or a focus on maintaining existing operations rather than expanding.

The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, but the low dilution risk suggests that the company is not likely to issue additional shares in the near term. The company's capital structure is relatively stable, with a low debt-to-equity ratio and a strong equity base.

There are no recent events or filings mentioned in the provided data that would significantly impact the company's operations or financial position. The company's financial performance and risk profile appear to be relatively stable, but there is no indication of significant recent developments that would alter its trajectory.

Tibet Aim Pharm Inc (002826.SZ) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals. This taxonomic update provides a clearer structural definition of the company’s operational focus, aligning its profile with industry-specific benchmarks for the first time in this analysis cycle. Alongside this classification, the company’s risk assessment framework has been initialized. Dilution risk is currently rated as low, suggesting that existing shareholders face minimal immediate threat from equity expansion. This stability in capital structure is a positive indicator for long-term value preservation, particularly in a sector where R&D funding often drives share issuance. Conversely, liquidity risk has been assessed at a medium level. This rating highlights potential constraints in trading volume or market depth, which could impact the ease with which large positions are entered or exited. For investors, this underscores the need for careful position sizing and timing, as price discovery may be less efficient than in more liquid peers. The company currently operates with no disclosed top holders and no index memberships, while being followed by a single analyst. This limited coverage and ownership concentration suggest that market sentiment may be driven by a narrow set of participants, amplifying the importance of the newly established risk and sector metrics for independent evaluation. [doc:002826.sz-ha-financials]

Net income surged 501.7% year-over-year to CNY 92.6 million, demonstrating significant bottom-line recovery and profitability improvement.

Free cash flow increased 387.3% to CNY 79.9 million, indicating strong cash generation capabilities relative to prior periods.

Debt-to-equity ratio of 0.02 is significantly lower than the cohort median of 0.18, suggesting a conservative and stable capital structure.

Revenue declined 4.6% year-over-year to CNY 636.3 million, signaling weakening top-line growth momentum in the current period.

Gross profit dropped significantly to CNY 522.5 million, down from CNY 522.5 million in FY0 but lower than FY-1 levels.

Four-year revenue CAGR is negative at -0.6%, revealing a long-term stagnation trend despite recent net income volatility.

Medium liquidity risk flags suggest potential challenges in meeting short-term obligations compared to more liquid peers.

Revenue ¥651.9M, −2,3% YoY; Operating income +162,2% YoY.

• ▍Revenue ¥651.9M, −2,3% YoY
• ▍Operating income +162,2% YoY
• ▍Net income +198,5% YoY
• ▍Free cash flow +210,2% YoY
• ▍Net margin 7.0%